Table 3.
Cox regression analysis for predictors of local HCC recurrence in all diabetic patients with complete response after TACE (N = 90).
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (year) | 0.99 (0.96–1.01) | 0.346 | ||
| Male gender | 0.86 (0.39–1.89) | 0.714 | ||
| Heavy alcohol consumption | 0.66 (0.34–1.28) | 0.224 | ||
| Hypertension | 0.48 (0.23–0.96) | 0.039 | 0.40 (0.19–0.86) | 0.019 |
| Cardiopulmonary disease | 1.34 (0.52–3.40) | 0.544 | ||
| CKD | 0.83 (0.33–2.11) | 0.695 | ||
| Viral hepatitis | 1.62 (0.88–2.97) | 0.119 | ||
| Liver cirrhosis | 2.04 (0.73–5.72) | 0.176 | ||
| Child–Pugh class B over A | 1.71 (0.82–3.53) | 0.150 | ||
| Metformin | 0.40 (0.21–0.74) | 0.003 | 0.28 (0.14–0.58) | 0.001 |
| Metformin dose > 500 mg/day | 0.78 (0.39–1.59) | 0.500 | ||
| Sulfonylurea | 0.76 (0.37–1.54) | 0.441 | ||
| Alpha glucosidase | 0.88 (0.39–1.99) | 0.765 | ||
| Thiazolidinedione | 1.49 (0.59–3.81) | 0.401 | ||
| DPP-4 inhibitor | 0.64 (0.35–1.16) | 0.140 | ||
| SGLT2i | 0.31 (0.04–2.23) | 0.242 | ||
| Insulin | 1.66 (0.59–4.65) | 0.334 | ||
| Statin | 0.68 (0.37–1.27) | 0.226 | ||
| HbA1C | 1.10 (0.92–1.34) | 0.287 | ||
| eGFR | 0.99 (0.98–1.00) | 0.078 | 0.99 (0.98–1.00) | 0.128 |
| Platelet, × 103/uL | 1.00 (1.00–1.00) | 0.532 | ||
| Prothrombin time (INR) | 3.30 (0.38–28.28) | 0.276 | ||
| Albumin, g/dL | 0.76 (0.41–1.40) | 0.378 | ||
| Total bilirubin, mg/dL | 1.25 (0.79–1.98) | 0.340 | ||
| ALBI grade | 1.34 (0.74–2.43) | 0.33303 | ||
| AFP > 20 ng/mL | 2.68 (1.42–5.05) | 0.001 | 2.18 (1.11–4.29) | 0.024 |
| Tumor size (cm) | 1.22 (1.01–1.48) | 0.037 | 1.34 (1.07–1.68) | 0.011 |
| BCLC A over 0 | 1.61 (0.79–3.27) | 0.189 | ||
| DEB-TACE | 1.38 (0.49–3.90) | 0.549 | ||
TACE transarterial chemoembolization, HCC hepatocellular carcinoma, HR hazard ratio, CI confidence interval, AFP alpha-fetoprotein, INR international normalized ratio, RFA radiofrequency ablation.